News

Click the title above to open the Applied Clinical Trials June 2019 issue in an interactive PDF format.

The World Health Organization tries to find a balance with its Road Map for Access on how to best approach research and pricing in Europe.

Undertaking an assessment of the POS can be coupled with the product profile and safety assessments of compounds prior to launching a clinical trial.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

Using a risk-based model to navigate the inherent changes and fluctuations in master protocol studies-and help maintain data integrity throughout.

Examining the fundamental changes required to successfully integrate clinical research into mainstream healthcare.

Crystal Stone and Amanda Coogan of Remarque Systems discuss how an RBM approach can help enhance the safety and efficiency of clinical trials.

Kyle Hogan, Director, eClinical Solutions, Clinical Ink, writes how however promising ePRO may be - its benefits may not be enough to overcome concerns that take an significant period of investment before generating business, patient benefits, and financial returns.

The case for evaluating drugs with real-world digital health data.

Abby Abraham, Vice President, Data Analytics, and RBM for OmniComm Systems, writes about a new survey that highlights gaps in the conversation surrounding the industry’s adoption and implementation of risk-based approaches to monitoring.

Moe Alsumidaie sits down with Ping Yeh, CEO and co-founder of StemoniX, to discuss how MicroOrgans will transform preclinical and clinical development in challenging areas like Alzheimer’s.